Asset Details
Do you wish to reserve the book?
Increased HbA1c relative to actual glycemic control in patients treated with sodium–glucose cotransporter 2 inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Increased HbA1c relative to actual glycemic control in patients treated with sodium–glucose cotransporter 2 inhibitors
Do you wish to request the book?
Increased HbA1c relative to actual glycemic control in patients treated with sodium–glucose cotransporter 2 inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Increased HbA1c relative to actual glycemic control in patients treated with sodium–glucose cotransporter 2 inhibitors
2026
Overview
Aims/Introduction Among patients with diabetes receiving sodium–glucose cotransporter 2 (SGLT2) inhibitors, HbA1c levels are higher than glycated albumin levels. This study therefore aimed to evaluate the discrepancy between HbA1c and glucose management indicator (GMI), an index of glucose management derived from continuous glucose monitoring, in this population. Materials and Methods This multicenter retrospective cohort study included patients with diabetes in whom HbA1c and GMI were simultaneously measured at two Japanese institutions. Data were collected when HbA1c levels had stabilized for at least 6 months after the administration of an oral hypoglycemic agent. The primary outcome was the discrepancy between HbA1c and GMI among patients receiving SGLT2 inhibitors and those receiving other oral hypoglycemic agents. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding factors. Results In total, 136 patients were included; of these, 109 and 27 were included in the SGLT2 inhibitor group and control group, respectively. After IPTW adjustment, the discrepancy between HbA1c and GMI (HbA1c–GMI) was significantly higher in the SGLT2 inhibitor group than in the control group (β = 0.42; 95% confidence interval 0.14–0.70; P = 0.003). Conclusions Patients receiving SGLT2 inhibitors may have increased HbA1c relative to their actual glycemic control.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Anemia
/ Continuous glucose monitoring
/ Diabetes
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - drug therapy
/ Female
/ Glucose
/ Glycated Hemoglobin - analysis
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Japan
/ Male
/ Sodium-glucose cotransporter
/ Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
